Study summary
A daily BTK inhibitor pill shrank relapsed brain lymphoma in two-thirds of patients
67%response rate
What was tested
Tirabrutinib, a once-daily BTK inhibitor pill that reaches the brain, for PCNSL that relapsed after methotrexate-based treatment.
What they found
- Overall response rate was 67%, with complete responses in 44%.
- Responses came within about 1 month; median duration was 9.3 months.
- Serious treatment-related side effects occurred in 27%.
What it means
Basis for a US accelerated-approval application; already approved in Japan.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.